Abstract
Elderly patients with advanced non-small cell lung cancer (NSCLC) are at higher risk for adverse events related to treatment of their disease. Chemotherapeutic agents used alone or together may increase survival, while leading to increased treatment related morbidity. New targeted agents used to treat NSCLC have yet to show sufficient improvement in disease outcomes. This review will discuss the current management of elderly patients with advanced non-small cell lung cancer.
MeSH terms
-
Age Factors
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Female
-
Frail Elderly*
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / mortality
-
Lung Neoplasms / pathology
-
Male
-
Neoplasm Invasiveness / pathology*
-
Neoplasm Staging
-
Palliative Care*
-
Quality of Life
-
Randomized Controlled Trials as Topic
-
Risk Factors
-
Survival Analysis
-
Treatment Outcome